115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39030)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66747)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3743)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39030)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup
    Meeting Abstract

    Cohen, A. D.; Voorhees, P. M.; Martin, T. G.; Lesokhin, A. M.; Hillengass, J.; Kaufman, J. L.; Schecter, J. M.; De Braganca, K. C.; Varsos, H.; Corsale, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008
    Meeting Abstract

    Braunstein, L. Z.; Mitchell, M.; Bandos, H.; Sikov, W. M.; Khan, A. J.; Chen, P. Y.; Ganz, P. A.; Jagsi, R.; White, J. R.; Cecchini, R. S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patterns of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastoma
    Meeting Abstract

    Mora, J.; Chan, G. C.; Morgenstern, D. A.; Amoroso, L.; Nysom, K.; Faber, J.; Wingerter, A.; Bear, M.; Rubio-San-Simón, A.; Tornøe, K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR)
    Meeting Abstract

    Winter, A. M.; Bharadwaj, S.; Herrera, A. F.; Iragavarapu, C.; Mirza, S.; Palomba, M. L.; Patel, S. S.; Gharibo, M. M.; Bernasconi, D.; Krimmel, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis
    Meeting Abstract

    Hagen, P.; Sidana, S.; Parker, T. L.; Walker, B. K.; Hoering, A.; Sanchorawala, V.; Zonder, J. A.; Kourelis, T.; D'Souza, A.; Landau, H. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Treatment of patients with dedifferentiated liposarcoma (DDLPS) with the MDM2-p53 antagonist brigimadlin and p53 function: A longitudinal analysis of circulating microRNAs (miRNAs) in a first-in-human phase Ia/Ib study
    Meeting Abstract

    Peltzer, A.; LoRusso, P.; Gounder, M. M.; Yamamoto, N.; Somaiah, N.; Lugowska, I. A.; Moreno, V.; Teufel, M.; Jayadeva, G.; Hesse, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Frontline brentuximab vedotin and CHP (A+CHP) in patients (pts) with peripheral T-cell lymphoma with less than 10% CD30 expression: Results from the phase 2 SGN35-032 study
    Meeting Abstract

    Iyer, S. P.; Jagadeesh, D.; Domingo-Domenech, E.; Benedetti, F.; Izquierdo, A. R.; Bouabdallah, K.; Vitolo, U.; Illidge, T. M.; Liu, J.; Shaikh, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Biomarker analysis of zanzalintinib in clear cell renal cell carcinoma from STELLAR-001
    Meeting Abstract

    Pal, S. K.; Medioni, J.; de Velasco, G.; Merchan, J. R.; Büchler, T.; Apolo, A. B.; Loriot, Y.; Wang, Z.; Jew, T.; Cao, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST)
    Meeting Abstract

    Wagner, A. J.; Trent, J. C.; Attia, S.; Agulnik, M.; Wilky, B. A.; Tap, W. D.; von Mehren, M.; Davis, E. J.; Zou, L.; Shah, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study
    Meeting Abstract

    Chandana, S. R.; Shepard, D. R.; Mehnert, J. M.; Chi, P.; Trent, J. C.; Psoinos, C. M.; Zhou, B.; Black, V.; Viswanathan, L.; Gozo, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save